At a glance
- Originator Tanabe Seiyaku
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Sep 1999 New profile
- 16 Sep 1999 Phase-I clinical trials for Inflammation in USA (PO)